drug_type
RELEVANT_DRUG
intervention_type
Vaccine
drug_description
Multi-epitope synthetic peptide cancer vaccine comprising HLA-A*0201–restricted peptides from EphA2, CMV pp65, and survivin, each fused to the tetanus toxoid P30 CD4 helper epitope; designed to elicit antigen-specific CD8+ T cells with CD4+ T-cell help in GBM.
nci_thesaurus_concept_id
C187131
nci_thesaurus_definition
A peptide vaccine comprised of three immunogenic tetanus toxoid epitope P30-linked tumor-associated antigen (TAA) peptides, P30-linked Ephrin receptor A2 (EphA2), P30-linked cytomegalovirus (CMV) matrix protein pp65 (65 kDa lower matrix phosphoprotein; UL83) and P30-linked survivin, with potential immunostimulating and antineoplastic activities. Upon administration, P30-linked EphA2/CMV pp65/survivin peptide vaccine P30-EPS may elicit a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EphA2, CMV pp65 and survivin. The tyrosine kinase receptor EphA2 and the inhibitor of apoptosis (IAP) family member survivin, overexpressed in certain tumor types, play key roles in tumor cell proliferation. The CMV pp65 protein is expressed in certain tumor types. The covalent linkage of P30 to the TAA peptides enhances TAA-specific anti-tumor immune responses, compared with the administration of the TAA peptides alone.
drug_mesh_term
Peptide Vaccines
drug_category
PEPTIDE VACCINE
drug_class
Vaccine
drug_delivery_route
Subcutaneous
drug_mechanism_of_action
Multi-epitope synthetic peptide vaccine comprising HLA-A*0201–restricted peptides from EphA2, CMV pp65, and survivin, each fused to the tetanus toxoid P30 CD4 helper epitope. The peptides are presented by APCs to prime and expand antigen-specific CD8+ cytotoxic T cells with CD4+ T-cell help, generating anti-tumor immune responses against cells expressing EphA2, survivin, and CMV pp65.
drug_name
P30-EPS Vaccine
nct_id_drug_ref
NCT05283109